Viral Infection Clinical Trials

36 recruitingLast updated: June 18, 2026

There are 36 actively recruiting viral infection clinical trials across 15 countries. Studies span Phase 1, Not Applicable, Phase 2, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Cincinnati, Ohio, United States, Washington D.C., District of Columbia, United States. Updated daily from ClinicalTrials.gov.


Viral Infection Trials at a Glance

36 actively recruiting trials for viral infection are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 1 with 10 trials, with the heaviest enrollment activity in Houston, Cincinnati, and Washington D.C.. Lead sponsors running viral infection studies include Children's Hospital Medical Center, Cincinnati, Valenta Pharm JSC, and Assistance Publique - Hôpitaux de Paris.

Browse viral infection trials by phase

Treatments under study

About Viral Infection Clinical Trials

Looking for clinical trials for Viral Infection? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Viral Infection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Viral Infection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting
Phase 1

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

InfluenzaAcute Respiratory Viral Infections
Valenta Pharm JSC36 enrolled1 locationNCT07645534
Recruiting
Phase 1

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Viral Infection
Baylor College of Medicine47 enrolled2 locationsNCT04013802
Recruiting
Phase 2

A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses

Respiratory Viral Infection
SynAct Pharma Aps96 enrolled11 locationsNCT07633288
Recruiting

Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection

Sensorineural Hearing LossViral InfectionCytomegalovirus Infections+2 more
Rigshospitalet, Denmark630 enrolled2 locationsNCT07635368
Recruiting

Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy

Immune responseBK polyomavirusBK Nephropathy+6 more
University Hospital, Grenoble100 enrolled1 locationNCT07347769
Recruiting

Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department

Respiratory Viral Infection
Hospices Civils de Lyon1,140 enrolled1 locationNCT07601412
Recruiting
Phase 1

Macrophage Regulation of Ozone-Induced Lung Inflammation

Respiratory Viral Infection
Robert Tighe, MD100 enrolled1 locationNCT05773001
Recruiting

Emergency PWAS in Respiratory Infectious Disease

Viral infectionsSepsisPneumonia+5 more
The University of Hong Kong2,000 enrolled1 locationNCT05336851
Recruiting
Phase 1

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed+4 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT05101213
Recruiting
Phase 1Phase 2

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Viral InfectionPrimary Immune Deficiency Disorder
New York Medical College40 enrolled7 locationsNCT04197596
Recruiting
Phase 3

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Acute Respiratory Viral Infection
Materia Medica Holding374 enrolled35 locationsNCT06715891
Recruiting
Phase 2

Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant

Allogeneic Stell Cell TransplantViral Infection
Children's Hospital Medical Center, Cincinnati180 enrolled1 locationNCT04230356
Recruiting
Not Applicable

Dime La VerDAD: Verify, Debunk, and Disseminate

COVID-19Health BehaviorInfluenza+2 more
University of Chicago1,400 enrolled4 locationsNCT06417762
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

InfluenzaAcute Respiratory Viral Infection
Valenta Pharm JSC300 enrolled11 locationsNCT07420985
Recruiting
Phase 1

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)Primary Immunodeficiency Disorders (PID)
Children's National Research Institute48 enrolled3 locationsNCT04691622
Recruiting
Not Applicable

Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection

Viral infectionsElderlyAntibiotics Overuse+1 more
Centre Hospitalier Universitaire, Amiens256 enrolled1 locationNCT07030673
Recruiting
Phase 3

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Respiratory Viral Infection
Joincare Pharmaceutical Group Industry Co., Ltd177 enrolled1 locationNCT07357051
Recruiting
Not Applicable

Effects of Mouthrinse on the Microbiome of the Oral Cavity and GI Tract

Viral InfectionMicrobial ColonizationOral Bacterial Infection+1 more
University of California, Irvine200 enrolled1 locationNCT05603650
Recruiting
Phase 2

Third Party Viral Specific T-cells (VSTs)

Viral reactivationViral InfectionInfection in an Immunocompromised Host
Children's Hospital Medical Center, Cincinnati750 enrolled4 locationsNCT02532452
Recruiting
Phase 1Phase 2

Donor-Derived Viral Specific T-cells (VSTs)

Viral reactivationallogeneic stem cell transplantViral Infection
Children's Hospital Medical Center, Cincinnati750 enrolled3 locationsNCT02048332